Search This Blog

Friday, August 27, 2021

COVID shot drives CanSinoBIO's first six-month profit since at least 2019

 

Chinese vaccine maker CanSino Biologics Inc (CanSinoBIO) said on Friday it had returned to operating profit of 802.3 million yuan ($123.79 million) in the first six months of 2021, driven by use of its COVID-19 shot. That compared with 123.0 million yuan of operating loss in the same period a year ago, CanSinoBIO said in a filing in the Hong Kong stock exchange. It marks the first six-month profit since at least 2019. The firm is yet to achieve full-year profits since it went public in 2018 in Hong Kong.

It reported 937.1 million yuan profit and total comprehensive income for the first six months of 2021. Its single-dose COVID-19 shot, named Ad5-nCoV, has been approved for use in countries including China, Mexico, Pakistan and Chile. The vaccine approvals were one of the major drivers for the sixth-month profit, CanSinoBIO said.

https://www.marketscreener.com/quote/stock/CANSINO-BIOLOGICS-INC-59318312/news/CanSino-Biologics-COVID-shot-drives-CanSinoBIO-s-first-six-month-profit-since-at-least-2019-36266624/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.